Clinical trials: Chronic Immobile Patients
- Condition Chronic Immobile Patients
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
COPD, COPD Exacerbation
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.
- Conditions
- COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders
- Trial name
- NCT01443845
- Testing
- Roflumilast
- Where
- 338 sites in United States, Argentina and 15 more
- Volunteers
- 2,354 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Tiotropium/Salmeterol Inhalation Powder in COPD
The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index (BDI)/Transition…
- Trial name
- NCT00668772
- Testing
- Tiotropium/Salmeterol, Salmeterol, Tiotropium
- Where
- 64 sites in United States, Austria and 15 more
- Volunteers
- 207 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD
Randomized,double-blind,multicenter,multinational,parallel-group,Phase III study to demonstrate the superiority of the triple fixed combination of beclometasone + formoterol + glycopyrrolate (BDP/FF/GB) administered via…
- Trial name
- TRILOGY (NCT01917331)
- Testing
- Beclometasone/Formoterol/Glycopyrrolate, Beclometasone/Formoterol
- Where
- Hungary
- Volunteers
- 1,368 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL administered with 5 micrograms tiotropium bromide solution for inhalation, delivered by the Respimat inhaler, once daily for four weeks in…
- Trial name
- NCT00696020
- Testing
- BI 1744 CL/tiotropium bromide fixed dose combination, tiotropium bromide, Respimat® Inhaler
- Where
- 37 sites in United States, Canada and 1 more
- Volunteers
- 360 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients
The primary objective of this trial is to investigate the effect of 6 weeks treatment with tiotropium + olodaterol fixed dose combination inhalation solution on lung hyperinflation and exercise tolerance in patients with COPD
- Trial name
- NCT01533922
- Testing
- Tiotropium, Olodaterol, tiotropium + olodaterol
- Where
- 44 sites in United States, Argentina and 8 more
- Volunteers
- 295 people
- Sponsor
- Boehringer Ingelheim
Hyperphosphatemia, Chronic Kidney Disease
An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease
Objective: In hyperphosphatemic pediatric participants with chronic kidney disease (CKD) to Evaluate the safety and tolerability of sevelamer carbonate Evaluate the efficacy of sevelamer carbonate on the control of serum…
- Trial name
- NCT01574326
- Testing
- Sevelamer carbonate
- Where
- 32 sites in United States, France and 3 more
- Volunteers
- 101 people
- Sponsor
- Genzyme, a Sanofi Company
Pulmonary Disease, Chronic Obstructive
Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to compare the systemic exposure to BI 1744 BS and tiotropium at steady state following inhalation of the fixed dose combination (FDC) of 10 μg BI 1744 CL plus 5 μg tiotropium bromide with the…
- Trial name
- NCT02231177
- Testing
- BI 1744 CL, BI 1744 CL/Tiotropium FDC, Tiotropium
- Volunteers
- 47 people
- Sponsor
- Boehringer Ingelheim
Chronic Cluster Headache
A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)
The main goal of this trial is to inform about long-term safety and tolerability of eptinezumab in participants with chronic cluster headache.
- Trial name
- CHRONICLE (NCT05064397)
- Testing
- Eptinezumab
- Where
- 31 sites in United States, Denmark and 7 more
- Volunteers
- 131 people
- Sponsor
- H. Lundbeck A/S
Pulmonary Disease, Chronic Obstructive
Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)
Open-label comparative multicentric cohort study in COPD patients with LABA/ICS, switched to either tiotropium/olodaterol and observed for 12 weeks approximately.
- Trial name
- NCT03954132
- Testing
- Spiolto® Respimat®, Triple-Therapy (LAMA/LABA/ICS)
- Where
- 75 sites in Germany
- Volunteers
- 469 people
- Sponsor
- Boehringer Ingelheim
Moderate to Severe Chronic Plaque-Type Psoriasis
4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
CAIN457A2304E1 was an extension study to two phase III studies, CAIN457A2304 and CAIN457A2307 (core studies). This extension study planned to collect up to four years of long-term safety, tolerability and efficacy data of…
- Trial name
- NCT01640951
- Testing
- AIN457 150 mg, AIN457 300 mg
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 675 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to assess the maintenance bronchodilator effects of the fixed dose combination versus monotherapies.
- Trial name
- NCT01437397
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate
- Where
- 222 sites in United States, Australia and 2 more
- Volunteers
- 1,692 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Cardiovascular Function in COPD Patients
The objectives of the study are to explore the effect of treatment with tiotropium + olodaterol fixed dose combination (FDC) compared to fluticasone propionate + salmeterol FDC on: reversal of left ventricular diastolic…
- Trial name
- NCT03055988
- Testing
- Tiotropium, Olodaterol, Fluticasone propionate
- Where
- 10 sites in Germany
- Volunteers
- 76 people
- Sponsor
- Boehringer Ingelheim
Chronic Myeloid Leukemia
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
To satisfy a postmarketing requirement, the sponsor has been requested to conduct a Phase 1/Phase 2 single-group clinical study to investigate the pharmacokinetics and preliminary safety and efficacy of omacetaxine following a…
- Trial name
- NCT02078960
- Testing
- Omacetaxine mepesuccinate
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 10 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Ischemic Stroke
Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Controlled study of stereotactic, intracranial injection of SB623 cells in patients with fixed motor deficits from ischemic stroke
- Trial name
- ACTIsSIMA (NCT02448641)
- Testing
- SB623 Implant (2.5M), SB623 Implant (5.0M)
- Where
- 65 sites in United States
- Volunteers
- 163 people
- Sponsor
- SanBio, Inc.
Pulmonary Disease, Chronic Obstructive
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in…
- Trial name
- NCT02296138
- Testing
- olodaterol, tiotropium
- Where
- 818 sites in United States, Argentina and 49 more
- Volunteers
- 7,903 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase II study is to evaluate the pharmacokinetics, safety, and tolerability of aclidinium/formoterol fixed dose combination (FDC 400/12 μg via the Almirall Inhaler and formoterol 12 μg via the Foradil®…
- Trial name
- NCT01551888
- Testing
- Aclidinium/formoterol 400/12μg, Formoterol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
AMPLIFY - D6571C00001 Duaklir USA Phase III Study
This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared…
- Trial name
- NCT02796677
- Testing
- Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg)
- Where
- 163 sites in United States, Bulgaria and 8 more
- Volunteers
- 1,595 people
- Sponsor
- AstraZeneca
Hypertension
26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
The primary objective of this trial is to assess the efficacy and safety of the fixed dose combinations telmisartan 40mg/amlodipine 10mg (T40/A10) or telmisartan 80mg/amlodipine 10mg (T80/A10) during open-label treatment for at…
- Trial name
- NCT00624052
- Testing
- fixed-dose combination of telmisartan 40mg+amlodipine 10mg, fixed-dose combination of telmisartan 80mg+amlodipine10mg
- Where
- 92 sites in Australia, Austria and 10 more
- Volunteers
- 838 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL administered with 5 microgram tiotropium bromide solution for inhalation, delivered by the Respimat® inhaler, once daily for four weeks in…
- Trial name
- NCT00720499
- Testing
- BI 1744 CL plus tiotropium bromide, Respimat® Inhaler
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 141 people
- Sponsor
- Boehringer Ingelheim
COPD
Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen
The main goal of this study is to evaluate the efficacy and safety of glycopyrronium bromide and indacaterol maleate and glycopyrronium bromide fixed dose combination (FDC) in patients with moderate COPD who switch from their…
- Trial name
- NCT01985334
- Testing
- Glycopyrronium, SABA, LABA
- Where
- 542 sites in Austria, Belgium and 21 more
- Volunteers
- 4,389 people
- Sponsor
- Novartis Pharmaceuticals